Seeking Alpha

Sinovac's (SVA) Enterovirus 71 (EV71) vaccine for hand, foot & mouth disease prevented the...

Sinovac's (SVA) Enterovirus 71 (EV71) vaccine for hand, foot & mouth disease prevented the infection of infants aged 6-35 months in a Phase III trial, showing a 95.4% efficacy rate and meeting the primary endpoint of the study. (PR)
Comments (1)
  • malc9141
    , contributor
    Comments (134) | Send Message
     
    This must be the only 'clean' China hybrid company. I also think it is a good long term bet (I hold stock).
    14 Mar 2013, 03:49 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|